BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC.
Jauset T, Massó-Vallés D, Martínez-Martín S, Beaulieu ME, Foradada L, Fiorentino FP, Yokota J, Haendler B, Siegel S, Whitfield JR, Soucek L.
Jauset T, et al. Among authors: yokota j.
Oncotarget. 2018 Apr 10;9(27):18734-18746. doi: 10.18632/oncotarget.24648. eCollection 2018 Apr 10.
Oncotarget. 2018.
PMID: 29721157
Free PMC article.